Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Nephrology
•
Glomerulonephritis
Do you take any special treatment considerations for elderly patients diagnosed with collapsing FSGS?
Related Questions
Do you prefer starting a SGLT2i before steroids in patients with IgA nephropathy and proteinuria > 1.0 gram/day who are unable to tolerate ACEi/ARB due to hypotension?
What is your approach to the management of secondary membranous nephropathy with nephrotic range proteinuria?
Are there patients with granulomatosis with polyangiitis on maintenance rituximab therapy for whom you do not co-administer glucocorticoid therapy?
Would you recommend genetic testing to determine if there is a potential underlying primary process in a patient with congenital solitary kidney who is presumed to have secondary FSGS?
When would you recommend starting immunosuppression in patients diagnosed with Henoch-Schönlein purpura and IgA nephropathy who have proteinuria < 1 gram per day and eGFR > 60 mL/min who are already on ACEi and SGLT2i?
How would you approach the treatment for patients with renal-limited ANCA vasculitis who have persistent proteinuria, hematuria, and ANCA titers and have completed a steroid taper and received three doses of rituximab?
How long do you continue maintenance immunosuppression in a patient with PR3 ANCA glomerulonephritis with pulmonary involvement?
Do you recommend initiating immunosuppression and plasmapheresis in patients with dialysis dependent AKI in the setting of anti-GBM disease who do not have pulmonary involvement?
What is your preferred initial therapy for patients with IgA nephropathy and more than 1 gram of proteinuria, given the recent approvals of sparsentan and budesonide alongside existing options like prednisone and ACEi/ARBs?
In patients with lupus nephritis, and MAHA with positive anti-phospholipid autoantibodies, what are the considerations to use or not use anti-coagulation therapy?
